RxDoctor Payments Data

Dione Rowe

Psychiatric/Mental Health · Winner, SDNPI 1174862924

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $91,865 of the $152,150 with a category attached, or 60.4%. Neurocrine Biosciences, Inc. accounts for 62.6% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $58,776, more than ten times the $4,516 reported in 2021. Among psychiatric/mental health clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$152,150in general payments, 2019–2025

Across 458 payments — averaging $332.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$95K
  • Alkermes, Inc.$55K
  • Otsuka America Pharmaceutical, Inc.$414
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$408
  • AbbVie$291
  • Johnson & Johnson$220
  • plus $927 from 16 others

What the payments were for

  • Consulting fees$27,98418%
  • Speaking & faculty fees$91,86560%
  • Travel & lodging$23,08615%
  • Food & beverage$9,1656%
  • Education$510%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,150 in reported general payments places this provider in the 95th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate62$378,966
AristadaAripiprazole Lauroxil71$208,239
Invega SustennaPaliperidone Palmitate62$181,393
NuplazidPimavanserin Tartrate13$63,184
RexultiBrexpiprazole43$59,876
VraylarCariprazine Hcl39$57,870
Abilify MaintenaAripiprazole13$37,846
LybalviOlanzapine/Samidorphan Malate23$36,496
Lupron DepotLeuprolide Acetate12$20,314
VivitrolNaltrexone Microspheres13$19,661
TrintellixVortioxetine Hydrobromide46$19,030
Clozapine81$3,391
Divalproex Sodium42$2,278
Olanzapine82$1,844
Olanzapine OdtOlanzapine21$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$95,284$378,96662 claims
Alkermes, Inc.Aristada, Lybalvi, Vivitrol$54,607$264,396107 claims
Johnson & JohnsonInvega Sustenna$220$181,39362 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$414$97,72356 claims
AbbVieVraylar, Lupron Depot$291$78,18551 claims
Acadia Pharmaceuticals IncNuplazid$36$63,18413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$19,03046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Winner

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →